Navigation Links
Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
Date:10/23/2007

CALGARY, Oct. 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its Clinical Trial Application (CTA) to begin a clinical trial using intravenous administration of REOLYSIN(R) in combination with cyclophosphamide, a chemotherapeutic agent as well as immune modulator, in patients with advanced cancers. The Principal Investigators are Dr. James Spicer of King's College in London, Dr. Johann de Bono and Dr. Kevin Harrington of The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, and Professor Hardev Pandha of the Royal Surrey County Hospital NHS Trust, Surrey and Mount Alvernia Hospitals.

The Company also intends to host a conference call Wednesday, October 24, 2007 to provide an update on its expanding clinical program. The dial-in details appear below.

"We are really looking forward to treating patients in this trial," said Principal Investigator Dr. James Spicer. "The hope is that it will provide valuable information about the relationship between oncolytic viral therapy and the immune response of the patient."

The trial (REO 012) is an open-label, dose-escalating, non-randomized trial of REOLYSIN(R) given intravenously with escalating doses of cyclophosphamide. A standard dose of REOLYSIN(R) is administered intravenously over five consecutive days, while an intravenous dose of cyclophosphamide is administered three days before REOLYSIN(R) treatment and continues through the course of the treatment cycle. The total number of patients studied will depend on the number of dose levels tested, but it is anticipated to be approximately 30 patients.

Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours including pancreatic, lung and ovarian cancers that are refractory (have not responded) to stan
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014  Actavis plc (NYSE: ... and Rhythm, a biopharmaceutical company, today announced that Actavis ... wholly owned subsidiary, Rhythm Health, Inc., which is developing ... of diabetic gastroparesis and other GI functional disorders. ... trial of relamorelin for the treatment of diabetic gastroparesis ...
(Date:10/22/2014)... 21, 2014 The North American crystal ... North America with analysis and forecast of revenue. This ... is expected to reach $623.6 million by 2018, at ... Browse through the TOC of the North American crystal ... in-depth analysis provided. This also provides a glimpse of ...
(Date:10/22/2014)... 2014 Involution Studios , a ... a new infographic, Understanding Ebola . The ... designed, easy to follow informative tool for anyone wanting ... symptoms and prevention. , "As the news has spread ... Ebola outbreak represents not only a healthcare crisis with ...
(Date:10/22/2014)... 2014 Currently offering a comprehensive ... D Weighing, Rice Lake, and Ohaus, Pipette.com has ... The Sartorius CPA Semi-Micro Balance is ideal for ... and user-friendly laboratory balance. , Sartorius is a ... laboratory balances are well known for their high ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3
... it has become the majority owner of First Choice ... the greater Harrisburg area. First Choice,s 13 clinics join ... providing high-quality rehabilitation in outpatient settings. ... as Select Physical Therapy will offer physical therapy and ...
... offering best-in-class clinical, commercial and consulting services to the ... a definitive agreement to acquire certain promotional and medical ... committed to divest in connection with obtaining regulatory approval ... transaction were not disclosed. The business will ...
... 17, 2012 Using growth factors derived from a ... Charles Runels have developed a simple, office-based procedure that ... sexual response. The preliminary results of this procedure, which ... a specific area on the upper wall of the ...
Cached Biology Technology:First Choice Rehabilitation Specialists Joins Select Medical 2inVentiv Health to Acquire SDI Promotional and Medical Audit Businesses From IMS Health 2inVentiv Health to Acquire SDI Promotional and Medical Audit Businesses From IMS Health 3inVentiv Health to Acquire SDI Promotional and Medical Audit Businesses From IMS Health 4inVentiv Health to Acquire SDI Promotional and Medical Audit Businesses From IMS Health 5"O-Shot™" May Improve Female Sexual Response 2"O-Shot™" May Improve Female Sexual Response 3
(Date:10/14/2014)... in Cancer Research shows SIRT6—a protein known ... promote the development of skin cancers by turning on ... sun-damaged skin cells. , Previously considered protective, SIRT6 is ... that help regulate genomic stability and prevent some of ... DNA damage, which can lead to cancer. This study, ...
(Date:10/14/2014)... – Scientists have sequenced the house fly genome for ... might expect from an insect that thrives in pathogen-rich ... Oct. 14 in the journal Genome Biology , ... and of how flies quickly adapt to resist insecticides, ... house flies (Musca domestica) carry and transmit more than ...
(Date:10/14/2014)... Sinai-led research team has discovered a new kind of stem ... cell that lines liver blood vessels, according to a study ... The existence of such a cell type contradicts current theory ... and may hold clues to origins of, and future treatment ... a single cell into a complex being made up of ...
Breaking Biology News(10 mins):Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2House fly genome reveals expanded immune system 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3
... -- When melatonin, a hormone secreted by the ... stem cells (MSCs) prior to their transplantation into the ... researchers in China found that the stem cells survived ... 80 percent of transplanted MSCs died within 72 hours ...
... of losers and a few lucky winners. This is the ... fish called Fouldenia , which first appears in the ... that wiped out more than 90 percent of the planet,s ... 359 million years ago created opportunities quickly exploited by a ...
... a body is like building a houseif you compromise structural ... a cellular level than in the case of epithelial sheets, ... the gut to mammary glands. As long as epithelial cells ... of building tissue barriers and constructing ducts goes smoothly. But ...
Cached Biology News:Melatonin pre-treatment is a factor that impacts stem cell survival after transplantation 2Melatonin pre-treatment is a factor that impacts stem cell survival after transplantation 3From obscurity to dominance: Tracking the rapid evolutionary rise of ray-finned fish 2From obscurity to dominance: Tracking the rapid evolutionary rise of ray-finned fish 3From obscurity to dominance: Tracking the rapid evolutionary rise of ray-finned fish 4A flip of the mitotic spindle has disastrous consequences for epithelial cells 2A flip of the mitotic spindle has disastrous consequences for epithelial cells 3A flip of the mitotic spindle has disastrous consequences for epithelial cells 4
Conveniently document gels, films and membranes with a high quality thermal printer. , Compact, footprint printer , Supplies 256 gray scale for high resolution, archive-quality thermal film prints...
... 384 Round Well ... Thermo Labsystems wide range ... ideal for high-throughput screening ... miniaturization of assays and ...
... a thermostable DNA polymerase purified from the ... procedures developed by Kaledin (1,2,3) for the ... activity from thermophilic bacteria. Amplification of DNA ... achieved with this enzyme. The enzyme has ...
HLA-DRbeta (DA2)...
Biology Products: